Business description
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk markets its products in more than 180 countries.
Management board & Supervisory board
| CEO |
| Lars Fruergaard Jørgensen |
| Management board |
| Karsten Munk Knudsen, Camilla Sylvest, Doug Langa, Henrik Wulff, Ludovic Helfgott, Marcus Schindler, Martin Horst Lange, Maziar Mike Doustdar, Monique Carter |
| Supervisory board |
| Helge Lund, Andreas Fibig, Anne Marie Kverneland, Henrik Poulsen, Jeppe Christiansen, Kasim Kutay, Laurence Debroux, Martin Mackay, Mette Bøjer Jensen, Stig Strøbæk, Sylvie Grégoire, Thomas Rantzau |
Company data
| Name: |
Novo Nordisk AS |
| Address: |
Novo Allé,DK-2880 Bagsværd |
| Phone: |
+45-4444-8888 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.novonordisk.com/ |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Medical Supplies |
| End of financial year: |
12/31 |
| Free Float: |
66.64% |
| IPO date: |
- |
Investor relations
| Name: |
Daniel Bohsen |
| IR phone: |
+45-3075-9085 |
| IR Fax: |
- |
| IR e-mail: |
DABO@novonordisk.com
|